Table 2.

Efficacy of ELQ-300 and ELQ-400 against blood-stage P. yoelii in mice^*

Treatment	4-day ED50	4-day NRD†	1-day ED50	1-day NRD
Oral ELQ-300	0.02	0.3	ND‡	> 20§
Oral ELQ-400	0.01	0.1	0.01	1
TD¶ ELQ-400	0.01	1	0.06	1

^*Values presented in mg/kg, N = 4 mice per group.

^†NRD = non-recrudescence/curative dose.

^‡ND = not determined.

^§20 mg/kg represents solubility limit of ELQ-300 in PEG-400. Higher concentrations not tested.

^¶TD = transdermal.